InvestorsHub Logo
Followers 10
Posts 282
Boards Moderated 0
Alias Born 10/13/2013

Re: Riskreturn168 post# 97813

Wednesday, 03/26/2014 1:16:20 PM

Wednesday, March 26, 2014 1:16:20 PM

Post# of 130506
Risk, Great post! I've made my peace with the idea that AMBS is likely to go Lympro alone quite a while ago. Of course, a great deal with a JV will make everyone happy. But from everything I have been able to research regarding Lympro I think AMBS sees it as a major home run with massive earnings potential. And diagnostics are substantially easier to bring to market than therapeutics. My sense is they are actively finding investors needed to run with it and then try to get fair deals with some more room for partnering through MANF orphans and Eltoprozine.

The funding from LPC made me think this scenario was likely. Going to Cavendish cements my thoughts on this. AMBS is seeking and able to get entrance to elite wealth. There is big money involved at Cavendish and more importantly, the type of people who can and do go in with their convictions. This is not like JP Morgan or Fidelity where the bottom line can get people fired if they make a bad bet. Visionaries bet on visionaries.

The main thing is that if AMBS can score big with Lympro on their own then they can afford to control a lot more of MANF and Phenoguard.

I am waiting patiently to see how this unfolds. Go AMBS!